Sight Sciences, Inc. (NASDAQ:SGHT) CEO Paul Badawi Sells 24,174 Shares

Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) CEO Paul Badawi sold 24,174 shares of the business's stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $2.30, for a total transaction of $55,600.20. Following the transaction, the chief executive officer now owns 6,010,580 shares in the company, valued at approximately $13,824,334. This represents a 0.40 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Paul Badawi also recently made the following trade(s):

• On Thursday, January 16th, Paul Badawi sold 24,819 shares of Sight Sciences stock. The stock was sold at an average price of $2.92, for a total value of $72,471.48.

Sight Sciences Trading Down 4.5 %

SGHT stock traded down $0.10 during midday trading on Tuesday, reaching $2.11. The company's stock had a trading volume of 91,285 shares, compared to its average volume of 209,147. The business's 50-day simple moving average is $2.66 and its 200-day simple moving average is $3.78. The company has a quick ratio of 9.74, a current ratio of 10.18 and a debt-to-equity ratio of 0.36. Sight Sciences, Inc. has a 52 week low of $2.04 and a 52 week high of $8.45. The stock has a market cap of $108.31 million, a PE ratio of -2.06 and a beta of 2.46.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last released its quarterly earnings data on Wednesday, March 5th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.01). Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%. The firm had revenue of $19.07 million for the quarter, compared to the consensus estimate of $18.98 million. During the same period in the previous year, the business earned ($0.22) EPS. As a group, sell-side analysts expect that Sight Sciences, Inc. will post -0.99 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Stifel Nicolaus reduced their price objective on shares of Sight Sciences from $5.00 to $4.00 and set a "buy" rating for the company in a research note on Thursday, March 6th. Needham & Company LLC restated a "hold" rating on shares of Sight Sciences in a report on Thursday, March 6th. UBS Group decreased their target price on Sight Sciences from $5.50 to $5.00 and set a "buy" rating for the company in a research report on Monday, January 27th. Piper Sandler dropped their price target on shares of Sight Sciences from $5.50 to $3.50 and set a "neutral" rating on the stock in a research report on Thursday, March 6th. Finally, Citigroup decreased their price objective on shares of Sight Sciences from $4.60 to $3.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. Five research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, Sight Sciences presently has an average rating of "Hold" and a consensus price target of $3.83.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of SGHT. ProShare Advisors LLC acquired a new stake in shares of Sight Sciences during the fourth quarter worth $36,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Sight Sciences in the fourth quarter valued at about $40,000. Arkadios Wealth Advisors bought a new stake in Sight Sciences in the 4th quarter valued at approximately $47,000. WealthTrust Asset Management LLC acquired a new position in Sight Sciences during the 4th quarter worth approximately $48,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Sight Sciences during the 4th quarter worth approximately $50,000. Institutional investors own 55.51% of the company's stock.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.